Table 4.

Summary of clinical adverse events during treatment with lidocaine patch 5%¹⁷

Body system event	TRAEs, n (% of patients)	TEAEs, n (% of patients)
Skin and subcutaneous tissue/rash	40 (12)	45 (14)
Nervous system	19 (6)	31 (9)
General disorders	16 (5)	26 (8)
Cardiac	2 (<1)	8 (2)
Musculosketetal, connective tissue, and bone disorders	1 (<1)	7 (2)
Infections	0	7 (2)
Eye	3 (1)	4 (1)
Psychiatric	2 (<1)	4 (1)
Respiratory, thoracic, and mediastinal	0	4 (1)
Immune system	3 (<1)	3 (<1)
Vascular	1 (<1)	2 (<1)
Ear/labyrinth	1 (<1)	2 (<1)
Renal and urinary	0	2 (<1)
Injury and poisoning	1 (<1)	1 (<1)
Neoplasms, benign, and malignant	0	1 (<1)
Surgical and medical	0	1 (<1)

Abbreviations: TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event.